EP1363528A4 - Methodes de diagnostic et de traitement des cardiopathies - Google Patents

Methodes de diagnostic et de traitement des cardiopathies

Info

Publication number
EP1363528A4
EP1363528A4 EP02707727A EP02707727A EP1363528A4 EP 1363528 A4 EP1363528 A4 EP 1363528A4 EP 02707727 A EP02707727 A EP 02707727A EP 02707727 A EP02707727 A EP 02707727A EP 1363528 A4 EP1363528 A4 EP 1363528A4
Authority
EP
European Patent Office
Prior art keywords
methods
heart disease
diagnosing
treating heart
treat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02707727A
Other languages
German (de)
English (en)
Other versions
EP1363528A2 (fr
Inventor
Mark C Fishman
John Mably
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
General Hospital Corp
Original Assignee
General Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by General Hospital Corp filed Critical General Hospital Corp
Publication of EP1363528A2 publication Critical patent/EP1363528A2/fr
Publication of EP1363528A4 publication Critical patent/EP1363528A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/40—Fish
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/03—Animal model, e.g. for test or diseases
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Food Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • General Physics & Mathematics (AREA)

Abstract

La présente invention se rapporte à des méthodes permettant de diagnostiquer une cardiopathie, telle qu'une insuffisance cardiaque, à des méthodes d'identification de composés qui peuvent être utilisées pour traiter ou prévenir une cardiopathie, ainsi qu'à des procédés d'utilisation de ces composés pour traiter ou prévenir une cardiopathie. L'invention se rapporte également à des systèmes de modélisation animale qui peuvent être utilisés dans des méthodes de criblage.
EP02707727A 2001-02-07 2002-02-06 Methodes de diagnostic et de traitement des cardiopathies Withdrawn EP1363528A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26733401P 2001-02-07 2001-02-07
US267334P 2001-02-07
PCT/US2002/003558 WO2002062205A2 (fr) 2001-02-07 2002-02-06 Methodes de diagnostic et de traitement des cardiopathies

Publications (2)

Publication Number Publication Date
EP1363528A2 EP1363528A2 (fr) 2003-11-26
EP1363528A4 true EP1363528A4 (fr) 2006-09-27

Family

ID=23018357

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02707727A Withdrawn EP1363528A4 (fr) 2001-02-07 2002-02-06 Methodes de diagnostic et de traitement des cardiopathies

Country Status (6)

Country Link
US (2) US20040152088A1 (fr)
EP (1) EP1363528A4 (fr)
JP (1) JP2004528828A (fr)
AU (1) AU2002242116B2 (fr)
CA (1) CA2437573A1 (fr)
WO (1) WO2002062205A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007028117A2 (fr) * 2005-09-02 2007-03-08 New England Medical Center Hospitals, Inc. Proteine p8 utilisee comme marqueur de l'insuffisance cardiaque
EP2179060B1 (fr) * 2007-07-18 2013-11-27 The Regents of the University of Colorado Expression différentielle de microarn de coeurs humains non insuffisants contre des coeurs humains insuffisants
US8200466B2 (en) 2008-07-21 2012-06-12 The Board Of Trustees Of The Leland Stanford Junior University Method for tuning patient-specific cardiovascular simulations
US9405886B2 (en) 2009-03-17 2016-08-02 The Board Of Trustees Of The Leland Stanford Junior University Method for determining cardiovascular information
US8315812B2 (en) 2010-08-12 2012-11-20 Heartflow, Inc. Method and system for patient-specific modeling of blood flow
KR101939778B1 (ko) 2012-07-27 2019-01-18 삼성전자주식회사 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치
ES2888024T3 (es) * 2016-02-15 2021-12-30 Kanagawa Prefectural Hospital Organization Reconocimiento de proteína similar a mucina de tipo membrana y aplicación clínica de la misma
CN113355332B (zh) * 2021-07-22 2022-09-06 青岛市妇女儿童医院 Heg1基因突变体及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018025A (en) * 1995-02-10 2000-01-25 Millenium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6018025A (en) * 1995-02-10 2000-01-25 Millenium Pharmaceuticals, Inc. Compositions and methods for the treatment and diagnosis of cardiovascular disease using rchd528 as a target

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FISHMAN MARK C ET AL: "Fashioning the vertebrate heart: Earliest embryonic decisions", DEVELOPMENT (CAMBRIDGE), vol. 124, no. 11, 1997, pages 2099 - 2117, XP002392539, ISSN: 0950-1991 *
FISHMAN MARK C ET AL: "Parsing the heart: Genetic modules for organ assembly", CELL, vol. 91, no. 2, 1997, pages 153 - 156, XP002392540, ISSN: 0092-8674 *
NAGASE T ET AL: "PREDICTION OF THE CODING SEQUENCES OF UNIDENTIFIED HUMAN GENES. XV. THE COMPLETE SEQUENCES OF 100 NEW CDNA CLONES FROM BRAIN WHICH CODE FOR LARGE PROTEINS IN VITRO", DNA RESEARCH, UNIVERSAL ACADEMY PRESS, JP, vol. 6, 1999, pages 337 - 345, XP000865804, ISSN: 1340-2838 *

Also Published As

Publication number Publication date
JP2004528828A (ja) 2004-09-24
WO2002062205A2 (fr) 2002-08-15
AU2002242116B2 (en) 2006-09-21
CA2437573A1 (fr) 2002-08-15
AU2002242116C1 (en) 2002-08-19
WO2002062205A3 (fr) 2003-09-12
US20090077681A1 (en) 2009-03-19
EP1363528A2 (fr) 2003-11-26
US20040152088A1 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
TR200003650T2 (tr) ß2-adrenerjik reseptör agonistleri
WO2004075865A3 (fr) Modulation selective d'une activite biologique induite par le recepteur tlr
HK1069767A1 (en) Methods for inhibiting ocular processes
WO2002099075A3 (fr) Prmt comme modificateurs de la voie p53 et methodes d'utilisation
WO2003101283A3 (fr) Marqueurs diagnostiques du cancer du poumon
WO2004032852A3 (fr) Procedes permettant de traiter l'arythmie cardiaque et de prevenir la mort due a l'arythmie cardiaque au moyen d'antagonistes du ngf
WO2005123116A3 (fr) Compositions et procedes pour le traitement ou la prevention de maladie liee a l'oxalate
WO2003087831A3 (fr) Proteines impliquees dans le cancer du sein
WO2005023202A3 (fr) Activation directe de la kinase activee par l'amp reposant sur l'utilisation de la kinase lkb1, suppresseur de tumeurs
DK1066056T4 (da) Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernmangel, fremgangsmåde til fremstilling af jerndextranforbindelsen og anvendelse af denne forbindelse til fremstilling af et...
WO2004084943A8 (fr) Utilisation d'antagonistes de la ghrelin ou du recepteur de la ghrelin pour traiter l'inflammation intestinale
EP1254260A4 (fr) Methodes pour diagnostiquer et traiter une maladie du coeur
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
WO2002062205A3 (fr) Methodes de diagnostic et de traitement des cardiopathies
WO2004045376A3 (fr) Methodes de criblage permettant d'identifier des traitements contre une maladie auto-immune
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
WO2004006856A3 (fr) Sequestration ou elimination du fer pour reduire la neurodegenerescence ou la progression de la maladie de parkinson
WO2003028536A3 (fr) Methodes permettant de diagnostiquer et de traiter les maladies cardiaques
WO2000000634A3 (fr) Procedes servant a inhiber helicobacter pylori
WO2002062204A3 (fr) Methodes de diagnostic et de traitement des maladies cardiaques
WO2005058280A3 (fr) Preparations a base d'enoximone et leur utilisation pour traiter l'hypertrophie cardiaque et l'insuffisance cardiaque
WO2002061430A3 (fr) Techniques et reactifs destines au traitement des troubles auto-immuns
WO2003028537A3 (fr) Methodes de diagnostic et de traitement de maladies et d'etats pathologiques touchant le coeur ou le systeme digestif, ainsi que du cancer
WO2004078142A3 (fr) Compositions et methodes de preventions et de traitement de maladies et d'etats pathologiques associes aux endotoxines
WO2003023048A3 (fr) Methodes de diagnostic et de traitement de maladies et affections associees a la proteine kinase c$g(l)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20030814

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

A4 Supplementary search report drawn up and despatched

Effective date: 20060829

17Q First examination report despatched

Effective date: 20061206

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110120